Validity of a Pediatric Version of the Glasgow Outcome Scale-Extended
Overview
Neurology
Authors
Affiliations
The Glasgow Outcome Scale (GOS) and its most recent revision, the GOS-Extended (GOS-E), provide the gold standard for measuring traumatic brain injury (TBI) outcome. The GOS-E exhibits validity when used with adults and some adolescents, but validity with younger children is not established. Because the GOS-E lacks the developmental specificity necessary to evaluate children, toddlers, and infants, we modified the original version to create the GOS-E Pediatric Revision (GOS-E Peds), a developmentally appropriate structured interview, to classify younger patients. The criterion, predictive, and discriminant validity of the GOS-E Peds was measured in 159 subjects following TBI (mild: 36%; moderate: 12%; severe: 50%) at 3 and 6 months after injury. Participants were included from two studies completed at the Pediatric Neurotrauma Center at Children's Hospital of Pittsburgh. We assessed the relationship among GOS-E Peds, the GOS, and the Vineland Adaptive Behavior Scales as well as other standardized measures of functional, behavioral, intellectual, and neuropsychological outcome. Premorbid function was assessed 24-36 h after injury. The GOS-E Peds showed a strong correlation with the GOS at 3 and 6 month time points. Criterion-related validity was also indicated by GOS-E Peds' association with most measures at both time points and at injury severity levels. The 3 month GOS-E Peds was associated with the 6 month GOS-E Peds, everyday function, behavior, and most cognitive abilities. Discriminant validity is suggested by weak correlations between both 3 and 6 month GOS-E Peds and premorbid measures. The GOS-E Peds is sensitive to severity of injury and is associated with changes in TBI sequelae over time. This pediatric revision provides a valid outcome measure in infants, toddlers, children, and adolescents through age 16. Findings support using the GOS-E Peds as the primary outcome variable in pediatric clinical trials.
Chong S, Zhu Y, Wang Q, Caporal P, Roa J, Chamorro F JAMA Netw Open. 2025; 8(3):e250438.
PMID: 40067302 PMC: 11897838. DOI: 10.1001/jamanetworkopen.2025.0438.
Nickerson T, Villo L, Eisner M, Lovett M, Chung M, OBrien N J Pediatr Intensive Care. 2024; 13(4):364-371.
PMID: 39629340 PMC: 11584268. DOI: 10.1055/s-0042-1743500.
Sargenius H, Ro T, Hypher R, Brandt A, Andersson S, Finnanger T Qual Life Res. 2024; 34(2):577-588.
PMID: 39572461 PMC: 11865218. DOI: 10.1007/s11136-024-03838-2.
MRI and Clinical Variables for Prediction of Outcomes After Pediatric Severe Traumatic Brain Injury.
Ferrazzano P, Rebsamen S, Field A, Broman A, Mayampurath A, Rosario B JAMA Netw Open. 2024; 7(8):e2425765.
PMID: 39102267 PMC: 11301548. DOI: 10.1001/jamanetworkopen.2024.25765.
Group A Streptococcal meningitis in children: a short case series and systematic review.
Dou Z, Li W, Hu H, Guo X, Hu B, Chen T Eur J Clin Microbiol Infect Dis. 2024; 43(8):1517-1531.
PMID: 38842766 PMC: 11271352. DOI: 10.1007/s10096-024-04863-2.